Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis
Open Access
- 20 April 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Musculoskeletal Disorders
- Vol. 21 (1), 1-9
- https://doi.org/10.1186/s12891-020-03294-2
Abstract
In 2013, denosumab was introduced as peri-operative adjuvant treatment for giant cell tumor (GCT) of bone as it inhibits osteoclast activity. It is suggested that denosumab relives pain, facilitate curettage in lesions requiring resection initially. However, controversy remains whether denosumab increases the risk of local recurrence after surgery. Medline, Embase and the Cochrane Library were comprehensively searched in June 2019 to identify studies investigating the clinical outcome of GCT of bone with and without peri-operative denosumab after surgery. Data were gathered and a meta-analysis was conducted. Ten studies with 1082 cases (169 in denosumab group, 913 in control group) were included. Overall, denosumab was associated with significantly higher risk of recurrence(P < 0.02) and inferior 5 year recurrence free survival(P = 0.000). Denosumab and curettage has a relatively higher risk of recurrence comparing to curettage alone(P = 0.07). The risk of recurrence is not significantly increased if denosumab was administered both preoperatively and postoperatively(P = 0.24). Administration of denosumab is associated with increased risk of recurrence due to a variety of reasons, though it is proven effective in relieving pain, enabling curettage and improved functional outcome. Post-operative denosumab is recommended as it continuously suppress/eliminate residue tumor cells.Other Versions
Funding Information
- Chinese Medical Science Academy Central scientific research institutes' basic scientific research business expenses Clinical and translational medicine research fund project (2019XK320010)
This publication has 33 references indexed in Scilit:
- The Clinical Approach Toward Giant Cell Tumor of BoneThe Oncologist, 2014
- Giant cell tumors of the sacrum—a nationwide study on midterm results in 26 patients after intralesional excisionEuropean Spine Journal, 2014
- Liquid Nitrogen or Phenolization for Giant Cell Tumor of Bone?Journal of Bone and Joint Surgery, 2014
- Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studyThe Lancet Oncology, 2013
- Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of BoneClinical Cancer Research, 2012
- Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone?The Journal of Bone and Joint Surgery. British volume, 2011
- Giant Cell Tumor of Bone: Risk Factors for RecurrenceClinical Orthopaedics and Related Research, 2010
- Giant cell tumor of the extremity: A review of 349 cases from a single institutionCancer Treatment Reviews, 2010
- Local Recurrence of Giant Cell Tumor of Bone After Intralesional Treatment with and without Adjuvant TherapyJournal of Bone and Joint Surgery, 2008
- Giant cell tumor of bone: treatment and outcome of 214 casesZeitschrift für Krebsforschung und Klinische Onkologie, 2008